Patient-Focused Drug Design, Enrollment Challenges, and More With Hannah Kemp
Aug 6, 2024
Tune into this month’s episode of the Scope of Things, where host Deborah Borfitz covers the use of AI for trial screening and recruitment purposes, a diabetes drug that may help treat sleep apnea, questionable advice from the FDA given to departing staffers, why the entire clinical trial enterprise may need to be revamped to eliminate systemic biases, and more. Hannah Kemp, vice president of strategic client engagement at Surgo Health, also joins the conversation to talk about how Surgo Health is helping companies recruit participants and her SCOPE 2024 presentation, as well as her thoughts on patient-focused drug design and the challenge of getting study sponsors on-board with enrollment strategies.
SHOW NOTES
News Roundup
AI for clinical trial screening
- Study in NEJM AI
AI for trial recruitment
- Study in Ophthalmology Science
Drug therapy for sleep apnea
- Study in NEJM
Investigation on departing FDA employees
- Article in The BMJ
N-Power Medicine/Merck collaboration
Youth prediabetes/diabetes dataset
- Link to POND web portal
Systemic biases in randomized controlled trials
- Study in Journal of Ethnicity in Substance Abuse
Guest
Hannah Kemp, vice president of Surgo Health
Hannah Kemp, vice president of strategic client engagement, Surgo Health
Hannah Kemp is the Vice President of Strategic Client Engagement at Surgo Health.
In her role, she helps clients develop more patient-centric healthcare and clinical trials leveraging Surgo’s novel data. Ms. Kemp has led large-scale projects across multiple therapeutic areas from infectious disease, maternal health, vaccines, and cancer and published. Ms. Kemp brings an ecosystem perspective having worked across healthcare from clinical trials to digital health to payors. Prior to joining Surgo, Ms. Kemp worked with Deloitte consulting as well as directly for the US government. She has a BA from the University of Virginia and an MPA from George Washington University.
